ArticleJAC-antimicrobial resistance2024
High prevalence of ceftriaxone-resistant and XDR
Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Temporal and geographic trends in extended-spectrum cephalosporins resistance among Neisseria gonorrhoeae isolates worldwide: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018-23.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Evidence for a Constrained Mutational Pathway to High-Level Spectinomycin Resistance inInternational journal of molecular sciences · 2026Article
- Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).The Lancet regional health. Western Pacific · 2026Article
- Rapid Cas13a-basedmSphere · 2026Article
- Emergence of Ceftriaxone-Resistant Neisseria gonorrhoeae penA-60-Carrying Strains, Thailand, 2025.Emerging infectious diseases · 2026Article
- Extensively drug-resistant (XDR)Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Treatment Diversification to Address the Continued Rise of Antimicrobial Resistance in Neisseria gonorrhoeae.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- A novel commensalJournal of clinical microbiology · 2025Article
- Surveillance of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- WHO global gonococcal antimicrobial surveillance programmes, 2019-22: a retrospective observational study.The Lancet. Microbe · 2025Observational
- The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo.Nature communications · 2025Article
- Antimicrobial resistance inThe Lancet regional health. Western Pacific · 2025Article
- Antimicrobial resistance inThe Lancet regional health. Europe · 2025Article
- Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness.NPJ vaccines · 2025Article
- High susceptibility to the novel antimicrobial zoliflodacin amongIJID regions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 6 countries.
Funding
Abstract
Objectives: Antimicrobial resistance (AMR) in Methods: Urethral swabs from males with urethral discharge were cultured. ETEST determined the MIC of five antimicrobials, and EGASP MIC alert values and EUCAST breakpoints were used. EGASP demographic, behavioural and clinical variables were collected using a standardized questionnaire. Results: From 437 male patients, 306 had positive Conclusions: A high prevalence of ceftriaxone-resistant, MDR and XDR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.